108 studies found for:    Hemophilia: Clinical Trials
Show Display Options
Rank Status Study
21 Recruiting Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa pegol
22 Recruiting Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: nonacog beta pegol
23 Completed A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia A With Inhibitors;   Haemophilia B;   Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
24 Completed Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Other: factor IX;   Drug: factor VIII
25 Completed Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
Condition: Hemophilia A
Interventions: Genetic: ReFacto AF;   Genetic: B-Domain deleted Recombinant Factor VIII;   Genetic: BDDrFVIII
26 Terminated A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Healthy
Intervention: Drug: NNC172-2021
27 Completed A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
28 Completed
Has Results
A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: rFVIII (BAY81-8973) on demand;   Biological: rFVIII (BAY81-8973) prophylaxis low-dose;   Biological: rFVIII (BAY81-8973) prophylaxis high-dose
29 Completed Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
30 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
31 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
32 Completed A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: activated recombinant human factor VII, long acting;   Drug: placebo
33 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
34 Active, not recruiting Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
35 Terminated Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Condition: Hemophilia A
Interventions: Drug: Rituxan;   Drug: prednisone
36 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
37 Completed Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
Condition: Hemophilia B
Intervention:
38 Completed Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Intervention: Drug: activated recombinant human factor VII
39 Completed
Has Results
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Conditions: Blood Coagulation Disorders;   Hemophilia A
Interventions: Biological: Recombinant Factor VIII (BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
40 Completed Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B;   Healthy
Interventions: Drug: NNC 0172-0000-2021;   Drug: placebo

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years